Advertisement
Australia markets close in 21 minutes

  • ALL ORDS

    7,836.20
    -101.30 (-1.28%)
     

  • ASX 200

    7,575.40
    -107.60 (-1.40%)
     

  • AUD/USD

    0.6542
    +0.0019 (+0.29%)
     

  • OIL

    83.92
    +0.35 (+0.42%)
     

  • GOLD

    2,347.10
    +4.60 (+0.20%)
     

  • Bitcoin AUD

    98,452.81
    +167.43 (+0.17%)
     

  • CMC Crypto 200

    1,388.80
    +6.23 (+0.45%)
     

  • AUD/EUR

    0.6097
    +0.0024 (+0.40%)
     

  • AUD/NZD

    1.0965
    +0.0008 (+0.07%)
     

  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     

  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     

  • DAX

    17,917.28
    -171.42 (-0.95%)
     

  • Hang Seng

    17,702.86
    +418.32 (+2.42%)
     

  • NIKKEI 225

    38,006.60
    +378.12 (+1.00%)
     

Erasca to Present at the Morgan Stanley Global Healthcare Conference

Erasca, Inc.
Updated ·1-min read
Erasca, Inc.
Erasca, Inc.

SAN DIEGO, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Morgan Stanley Global Healthcare Conference. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a fireside chat at 12:55 pm Eastern Time on Wednesday, September 14, 2022, at the Sheraton Hotel in New York, New York. Drs. Lim and Chacko will also participate in one-on-one investor meetings.

A live webcast of the event will be available online at https://cc.webcasts.com. An archived replay of the event will be available until December 14, 2022, following the webcast at Erasca.com/events.

About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled what we believe to be the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Source: Erasca, Inc.